Product Description: Pimasertib (AS703026) is a highly selective, ATP non-competitive allosteric orally available MEK1/2 inhibitor[1][2].
Applications: Cancer-Kinase/protease
Formula: C15H15FIN3O3
References: [1]Kim K, et al. Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo. Br J Haematol, 2010, 149(4), 537-549./[2]Yoon J, et al. MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy. Cancer Res, 2011, 71(2), 445-453./[3]Park SJ, et al. The MEK1/2 inhibitor AS703026 circumvents resistance to the BRAF inhibitor PLX4032 in human malignant melanoma cells. Am J Med Sci. 2013 Dec;346(6):494-8.
CAS Number: 1236699-92-5
Molecular Weight: 431.20
Compound Purity: 99.88
Research Area: Cancer
Solubility: DMSO : ≥ 100 mg/mL
Target: MEK
English
Deutsch
